ClinicalTrials.gg
RecruitingNCT06568419Updated Apr 23, 2026

eBehandling - Health and Work for Patients in Specialist Mental Health Care

An interventional study of Transdiagnostic, work-focused Cognitive Behavioural Therapy in Anxiety and Depression, sponsored by Solli Distriktspsykiatriske Senter. Recruiting at 9 sites in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Depression with a site in Norway — 22 open to participants now, 31 under way, none of them phase 3. Depression · Norway.

Planned enrollment
21st of 81
400 · median 170
Started
2024
with 2 others
No phase
66 of 109
16 open now
Primary completion
2027-04
later than 18 of 30 live
Registered
95th of 109
by date

Among the 109 studies in Depression with a site in Norway, this one is the 21st largest by planned enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2024, is one of 66 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 95th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

22 of the 109 studies in Depression with a site in Norway are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Depression with a site in Norway, or all of them as a file.
02

Study summary

Mental health problems and disorders affect one in every five amongst the working- age adults in the countries of the Organization for Economic Cooperation and Development. This constitutes a major public health challenge that also has large implications for work participation and productivity.

Major depression and anxiety are the most prevalent of the mental disorders and are therefore named common mental disorders (CMD). CMD have become a major cause of work absenteeism, with 30% of all sick leave in Norway being due to CMDs in 2024.

Early interventions addressing psychological aspects and vocational challenges related to work have shown a positive effect on return to work. Therefore, finding ways to increase availability and reduce barriers to evidence-based treatments seems a viable route to reducing mental health's impact on sick leave and absenteeism.

Research show that improvement in symptoms from ordinary psychotherapy has little impact on sick-leave. The same results have been found for internet-based cognitive therapy (ICBT). One of the challenges in specialised mental health care is that the work focus has been an additive or extended part of the treatment, not integrated in the treatment itself.

Several studies have been conducted on psychological treatments that specifically target return to work for people with CMDs. Systematic reviews have shown that work-focused therapy has a small, but significant effect over treatment as usual on return to work and finds that 20% more workers in the intervention groups had returned to work, compared to control groups.

The availability of traditional therapy is scarce and there is an need for new effective ways of delivery. internet-based cognitive therapy has been shown to be as effective as traditional therapy in many systematic reviews and meta analysis and seems a good approach to reach the goal of increasing availability.

To account for the heterogene group of people on sick leave the investigators have created a transdiagnostic, work-focused internet-based cognitive behaviloural therapy program.

This study aims is to is to investigate the utility and use of this treatment program for patients with common mental health disorders on sick leave or work assessment allowance. This includes the user experience of participation and experienced utility of the treatment program.

Read the detailed description

Study aims The main aim of the current study is to investigate the utility and use of a digital transdiagnostic work-focused CBT treatment program for patients with common mental health disorders on sick leave or work assessment allowance. This includes the user experience of participation and experienced utility of the treatment program. Secondary aims are related to mediators and moderators of treatment efficacy and the participants' experience with the program.

Research questions

  1. To what extent does the treatment program impact Return to Work, self-reported symptoms, and everyday functioning?
  2. To what extent do clinical, work-related and demographic factors affect treatment adherence and treatment response?
  3. To what extent do adherence and changes in work-related self-efficacy predict outcomes?
  4. What type and frequency of negative effects does participants report?
  5. How do participants describe their experience of use and utility of the program, as well as its challenges and benefits?

    Hypotheses of main effects H1a. The investigators expect a large main effect of treatment on total percentage sick leave from pre- to post treatment, with gains maintained at follow up.

    H1b. The investigators expect a large main effect of treatment on the number of participants with full return to work from pre- to post treatment, with gains maintained at follow up.

    H2. The investigators expect a large main effect of treatment on reduction on symptoms of depression and anxiety.

    H3. The investigators expect a positive main effect of treatment on Return to Work Self-Efficacy, from pre to post treatment, and sustained through follow up.

    Hypotheses of moderating and mediating effects and predictors of outcome H4. The investigators expect a negative relationship between duration of baseline work absenteeism and degree of return to work at post. Baseline work absenteeism will moderate the relationship between treatment and return to work.

    H5a. The investigators expect treatment credibility at baseline to be predictive of treatment adherence.

    H5b. The investigators expect that treatment adherence will be a mediator between treatment credibility and treatment outcome.

    H6. The investigators expect changes on the Return to Work Self-Efficacy Scale to predict the degree of absenteeism post treatment.

    H7. The investigators expect change on the Return to Work Self-Efficacy Scale to be a mediator between baseline absenteeism and return to work post-treatment.

    H8. The investigators expect higher depression scores (PHQ-9/CORE-OM score) to be a moderator between treatment credibility and treatment outcome and adherence.

    H9. The investigators expect that fewer than 10% of participants experience negative effects caused by participation, as measured by the Negative Effects Questionnaire (NEQ).

    Measures

    Demographic variables. Self-reported data will be collected on gender, age, level of education, length and degree of sick leave, length of mental health problems and marital status.

    Primary and secondary F-diagnosis (ICD-10) will be reported by the eTherapist. Questionnaires.

    Primary outcome measures: The reduction in the degree of sick leave is one of our primary outcomes and will be measured through self-report.

    The Return to Work Self-Efficacy Scale

    Secondary outcome measures:

    The Generalized Anxiety Disorder-7

    The Patient Health Questionnaire-9

    The Work and Social Adjustment Scale

    CORE-OM

    CORE-10 The Negative Effects Questionnaire

    An adapted version of the Credibility Rating Scale

    System data on user behaviour. Data on use and user behaviour will be extracted from the system and combined with data from the self-report questionnaires collected. Information about the actual program use will be generated by the e-health platform Youwell. The data includes the extent to which participants complete the treatment, where and when the participants drop out, and how long the participants need to complete individual parts.

    Further The investigators also will analyse how long each session lasts and what system and platform the participants use. Each eBehandling location will also maintain local statistics on the number of assessment interviews, participants included and excluded to assess acceptance in the patient population and hospital setting.

    Qualitative in-depth interviews. Two months after completion of the program, a subset of participants will be invited to an in-depth interview. The investigators will use purposive sampling to select participants who represent a diverse range of demographics (age, gender) and outcomes (treatment responders and non-responders). The investigators aim to recruit a total of 20 participants for the qualitative interviews, likely ensuring richly-textured information on a broad array of participant experiences.

    The treatment intervention is a digital transdiagnostic work-focused cognitive behaviour therapy program. The program consists of seven modules consisting of psychoeducational texts, imagery and models, in addition to therapist-tailored tasks for the participants. The treatment model is based on traditional CBT principles and adjusted to target transdiagnostic maintaining mechanisms in anxiety and depression such as frequent negative emotions and aversive reactions to these that leads to various forms of avoidant coping that serve to reinforce the negative emotional cycle.

    Treatment will be given by trained eTherapists with specific training in the eBehandling - health and work protocol. Further the participants will be given a one-day introduction on the use of W-CBT within a digital format by the authors of the program.

    Quantitative analyses. In order to identify factors associated with treatment success and outcomes, hierarchical linear mixed modelling analyses (HLM, "multilevel") will be conducted. The models will be checked if the participants fulfil the model assumptions of normality of residuals, linearity and homoscedasticity. The dependent variables are sick leave, work related self-efficacy (as measured by RTWSE-11), depression severity (PHQ-9), anxiety (GAD-7), well-being, symptoms, risk and function (CORE-OM) and impairment in functioning (WSAS). The predictors are: Treatment (time), duration of sick-leave prior to treatment, treatment credibility, work related self-efficacy, depression severity and adherence. Comparisons are modelled through main effect and interaction effect analysis (e.g. Time x "Baseline work absenteeism" interaction). Predictors will be centred using grand mean centering. T-values and degrees of freedom will be estimated using "Sattertwaite" correction. The effects sizes will be converted from t-values and degrees of freedom to Cohen's d. Corrections for multiple analyses will be done by using Jaccard's correction to decrease risk of Type I error when applying several statistical tests.

    Qualitative analyses. Transcribed interviews will be analysed with the software NVivo 14 using reflexive thematic analysis. By comparing the individual accounts, The investigators want to identify both patterns of commonalities and differences in participants' experiences and formulate these as themes.

    Power analyses As stated by Van Voorhis and Morgan (2007): "if the circumstances allow, a researcher would have better power to detect a small effect size with approximately 30 participants per variable. Following this rule of thumb, The investigators plan for 30 participants per predictor (unique main effects), thus a total sample size of 300 participants. Calculating a drop-out rate of 30% gives a total sample size of N = 390.

    Procedure Inclusion will be open for 18 months, planned from September 2024. Participants will be recruited from outpatient specialised mental health care facilities in the Western Norway Regional Health Authority and South-Eastern Norway Regional Health Authority. After recruitment, each participant will undergo an assessment for eligibility where inclusion and exclusion criteria are evaluated. If eligible, participants are asked to sign a written informed consent to participation before enrolment in the study. Participants can at any time during treatment withdraw their consent. In this case the participants will be able to continue treatment, but their user data will not be exported for research purposes.

    The main form of contact between participant and eTherapist will be via asynchronous messages. If asked for by the participant, or evaluated as necessary by the eTherapist there will be contact via phone or face-to-face.

    After 12 weeks the participants will be given a concluding session face-to-face where the next step is decided: End treatment, further treatment within the specialist mental health care services or referred to a different treatment option. Regardless of this the participants will have access to the treatment program, without therapist contact, for six months after completion.

    Ethical considerations

    The therapist's level of competence

    The therapists giving the treatment program are clinical psychologists or have at least a bachelor degree in health. All therapists are trained in eTreatment in general, this program specifically and are given weekly or bi-weekly guidance on eTherapy within their workplace and by the project group.

    Monitoring suicidal risk or behaviour Participants will each week answer question 10 (suicidal ideations) of the Montgomery and Åsberg Depression Rating Scale and the total CORE-10. Both of these questionnaires have a cut-off for risk which, if surpassed, leads to an automatic text message and e-mail to the participants' eTherapist and local program supervisor. The eTherapist, or the program supervisor contacts the participant and follows their local procedure on assessing suicidal risk and take precautionary measures as deemed necessary.

    Transdiagnostic treatment for specific or comorbid diagnosis There is compelling evidence that transdiagnostic treatment protocols are effective in influencing the underlying mechanisms of CMDs through the reduction of fear and avoidance of-, and increasing acceptance of emotions, physical sensations and establishing alternative, more adaptive behaviours. This is found in both face-to-face therapy and ICBT. As The investigators have developed the treatment in the current study on these established principles The investigators see no imminent increased risk of reduced effect of the treatment on CMDs in this study.

    In the case of participant drop out If a patient drops out of treatment, or together with their eTherapist concludes that the treatment program of this study is not suitable, the participants will be given access to other, suitable treatment either via "eBehandling" or face-to-face treatment at their local District Psychiatric Center.

    Data and privacy protection The Youwell platform and concerns of health information have been processed and approved for clinical use via the Western Norway Regional Health Authority based on a risk and vulnerability analysis and Data Protection Impact Assessment

    Financing sources The study is currently funded by Solli DPS and previously assigned strategic funding from the Western Norwegian Regional Health Authority. The investigators will apply for funding from the Western Norwegian Regional Health Authority.

    Conflicts of interest No conflicts of interest are stated by the research project group.

03

Conditions studied

  • Anxiety
  • Depression

Browse trials for

Keywords

  • Sick Leave
  • Absemteeism
  • Transdiagnostic treatment
  • Internet-based Cognitive Behavioural Therapy
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 400 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Solli Distriktspsykiatriske Senter is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. being an outpatient in specialised mental health care service,
  2. above 18 years old,
  3. full or graded sick leave, or on work assessment allowance
  4. primary diagnosis of F30 - F40 (ICD-10),
  5. currently employed.

Exclusion criteria

Exclusion Criteria:

  1. ongoing psychotic disorder and/or mania,
  2. ongoing substance abuse, incl. sedative medications,
  3. ongoing episode of major depression,
  4. organic brain disease,
  5. severe reading and writing difficulties.
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Digital transdiagnostic work-focused CBT treatment program

    digital transdiagnostic work-focused CBT treatment program for patients with common mental health disorders on sick leave or work assessment allowance

    Behavioral: Transdiagnostic, work-focused Cognitive Behavioural Therapy

Interventions

  • BehavioralTransdiagnostic, work-focused Cognitive Behavioural Therapy

    Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.

07

What researchers measure

Primary outcomes

  1. Degree of Sickleave

    Self-reported degree of sick leave (percentage)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

  2. Return to Work Self-efficacy 11

    11-item questionnaire measuring an individual's confidence in their ability to work and perform work tasks. Items are scored on a scale from 1 ("Totally disagree") to 6 ("Totally agree"). Items 2 and 6 are reversed.

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

Secondary outcomes

  1. Generalized Anxiety Disorder-7

    measure of worry and anxiety and consists of seven items scored from 0 ("Not at all") to 3 ("Nearly every day") and one additional item measuring how the symptoms affect functioning.

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

  2. Patient Health Questionnaire-9

    measures depression severity. The measure consists of nine items scored from 0 ("Not at all") to 3 ("Nearly every day").

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

  3. The Work and Social Adjustment Scale

    measures impairment in functioning. The measure consists of five items scored from 0 (not at all impaired) to 8 (very severely impaired)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

  4. CORE-OM

    a 34-item self-report, measuring well-being, symptoms, elements of risk, and function on a five-point scale ranging from "not at all" to "most, or all the time".

    Time frame: baseline, 6 weeks, 12 weeks, 6 months and 12 months

  5. CORE-10

    a ten item self-report measuring symptoms, well-being, functioning and risk on a five-point scale ranging from "not at all" to "most, or all the time"

    Time frame: at 2, 4, 8 and 10 weeks

  6. The Negative Effects Questionnaire

    a 20-item questionnaire evaluating adverse or unwanted events during treatment. Participants report whether a specific event occurred during treatment ("Yes"/"No") and then indicate how negatively they were affected by it on a scale ranging from 0-4.

    Time frame: at 12 weeks

Other outcomes

  1. Credibility Rating Scale

    An adapted version of the Credibility Rating Scale (Borkovec \& Nau 1972) will be used to assess treatment credibility. The scale consists of five items where participants rate their credibility/expectancy-for-improvement on a 10-point scale.

    Time frame: baseline, 6 weeks and 12 weeks

  2. Montgomery and Åsberg Depression Rating Scale

    Participants will each week answer question 10 (suicidal ideations)

    Time frame: baseline and every week for 12 weeks (until the end of the treatment program)

08

Study locations

3 of 9 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Aug 23, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06568419
Lead sponsor
Solli Distriktspsykiatriske Senter
Collaborators
Sykehuset Innlandet HF, Sykehuset Ostfold, Sykehuset i Vestfold HF, University Hospital, Aker, Helse Fonna, Helse-Bergen HF, Vestre Viken Hospital Trust, Macquarie University, Australia, Diakonhjemmet Hospital, Haukeland University Hospital
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Dec 1, 2024
Primary completion
Apr 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Henning Monsen, MSc
Contact
henning.monsen@Solli.no
0047+47018243
Pål William Wallace, PhD
Contact
pal.wiliam.wallace@solli.no
004745356200
Pål William Wallace, PhD
study director · Solli DPS
Kristine Sirevåg, MSc
study chair · Solli DPS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion